03:48 PM EST - Acasti Pharma : announced its financial results for the three-month period ending August 31, 2013. Revenues were $266,000 for the quarter, versus $237,000 for the quarter ended August 31, 2012. Adjusted EBITDA was negative $(1,755,000) for the quarter ended August 31, 2013, versus negative $(1,037,000) in the corresponding prior-year quarter. A net loss of $(3,238,000) or $(0.04) per share was recorded for the current quarter, versus a net loss of $(1,752,000) or $(0.02) per share in the same quarter last year. Acasti Pharma
shares V.APO are trading up $0.10 at $2.35.
